News | November 23, 2025
Cosmo and Glenmark receives market authorization of Winlevi in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Winlevi is authorized in EU for the treatment of acne vulgaris
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Glenmark will begin distribution in November 2025
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The payment is in accordance with the agreed contractual terms
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
